Sp129
PHAGE THERAPY- WHERE ARE WE HEADED?
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
Through the history of gut microbiome research, basic, translational, and clinical studies revealed many critical roles played by gut-resident bacteria in affecting human health and disease. However, due to several technical and conceptual limitations, other microbes (such as fungi and viruses) have received comparatively little attention by gut microbiome researchers. This session brings together thought leaders from the microbiome research community whose innovative research focuses on fungi and bacteriophages (viruses that infect bacteria), focuses on the importance of non-bacterial members of the gut microbiome, the roles they play in health and disease, and their therapeutic potential.
Through the history of gut microbiome research, basic, translational, and clinical studies revealed many critical roles played by gut-resident bacteria in affecting human health and disease. However, due to several technical and conceptual limitations, other microbes (such as fungi and viruses) have received comparatively little attention by gut microbiome researchers. This session brings together thought leaders from the microbiome research community whose innovative research focuses on fungi and bacteriophages (viruses that infect bacteria), focuses on the importance of non-bacterial members of the gut microbiome, the roles they play in health and disease, and their therapeutic potential.
Presenter
University of California San Diego
Tracks
Related Products
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…